Obesity therapeutics: The end of the beginning.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 33826913.
- Also identified by DOI 10.1016/j.cmet.2021.03.012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Obese non-diabetic patients receiving semaglutide, an injectable long-acting GLP-1 receptor agonist, in a large randomized placebo-controlled trial, lost and maintained ∼15% of their body weight for over a year (Wilding et al., 2021). This impressive result is likely to usher in a new era of anti-obesity drugs based on hormones that suppress food intake, largely through acting on the brain.
Medical subject headings
- Anti-Obesity Agents
- Obesity